Rhinovirus diagnostics market seen reaching $2.33 billion by 2030

The rhinovirus diagnostics market is projected to grow from $1.71 billion in 2026 to $2.33 billion by 2030, according to The Business Research Company. The forecast points to rising demand for rapid respiratory testing, broader multiplex panels and AI-assisted interpretation as respiratory illness monitoring expands worldwide.

Why it matters: - Rhinovirus diagnostics help confirm infections that cause the common cold and support faster treatment decisions. - Stronger testing demand could improve infection control and patient outcomes as respiratory illnesses remain widespread. - The market is also tied to broader spending on infectious disease monitoring and diagnostic infrastructure.

What happened: - The Business Research Company released its Rhinovirus Diagnostics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report puts the market at $1.71 billion in 2026, up from $1.58 billion in 2025. - The report forecasts the market will reach $2.33 billion by 2030, implying an 8.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Historical growth has been driven by rising common cold and respiratory infection rates, broader use of molecular diagnostics, better hospital lab testing, and the limits of traditional virus culture methods. - The report says rapid point-of-care diagnostic tests will be a major growth driver. - AI-driven diagnostic interpretation tools are expected to gain more use. - Multiplex testing panels that detect multiple respiratory pathogens are expanding. - Investment in infectious disease monitoring systems is increasing. - Precision medicine approaches for respiratory conditions are also supporting demand. - Emerging trends include AI-enhanced respiratory pathogen identification, broader use of multiplex PCR respiratory virus panels and cloud-based surveillance platforms. - The report also points to growth in point-of-care rhinovirus devices and more sensitive molecular assays for early detection. - Respiratory disorders are rising, in part because air pollution can weaken lung function over time. - The National Center for Biotechnology Information said in December 2023 that COPD cases are projected to rise by 112 million to 592 million by 2050, or 9.5% of the eligible population. - The Office for National Statistics said in April 2025 that UK healthcare spending reached about $29.88 billion (£317 billion) in 2024, up 6.5% from 2023. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated trend analysis. - The Business Research Company says it has more than 30,000 reports across 27 industries and 60+ geographies. - The company says its Global Market Model provides updated forecasts for decision-making. - More information is available in the full report and a free sample.

Between the lines: - The forecast suggests the market is shifting from basic viral detection toward faster, more automated and more integrated respiratory testing. - AI and multiplex panels are likely to matter most where providers want quicker answers from a single sample. - The growth case depends partly on broader healthcare spending and more aggressive monitoring of respiratory disease trends.

What's next: - The report expects continued adoption of rapid, multiplex and AI-assisted diagnostic tools through 2030. - Asia-Pacific’s faster growth could reshape regional competition and investment priorities. - More hospital, lab and point-of-care use may follow as respiratory surveillance needs expand. - The full market report and sample request are available through The Business Research Company.